About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects

The semi-parametric proportionalhazards model is widely adopted in randomized clinical trials withtime-to-event outcomes, and the log-rank test is frequently used to detect apotential treatment effect. Immuno-oncology therapies pose unique challenges tothe design of a trial as the treatment effect may be delayed, which violatesthe proportional hazards assumption, and the log-rank test has been shown tomarkedly lose power under the non-proportional hazards setting. A novel designand analysis approach for immuno-oncology trials is proposed through apiecewise treatment effect function, which is capable of detecting apotentially delayed treatment effect. The number of events required for thetrial will be determined to ensure sufficient power for both the overalllog-rank test without a delayed effect and the test beyond the delayed periodwhen such a delay exists. The existence of a treatment delay is determined by alikelihood ratio test with resampling. Numerical results show that the proposeddesign adequately controls the Type I error rate, has a minimal loss in powerunder the proportional hazards setting and is markedly more powerful than the log-ranktest with a delayed treatment effect.

Keywords: Clinical trial design; Immuno-oncology; Change point; Non-proportional hazards